ADC 테라퓨틱스(ADCT)는 NYSE에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.05 (-0.94%), 시가총액 $0.41B, 52주 최저~최고 $1.89 ~ $4.88.
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal
ADC 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
ADC 테라퓨틱스의 현재 주가는 $1.05 (-0.94%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
ADC 테라퓨틱스의 시가총액은 약 $0.41B입니다.
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated a